Identification
Instrument name
ACACIA PHARMA
Symbol
ACPH
ISIN code
GB00BYWF9Y76
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Market organization
EuronextBrussels
Capitalization compartment
Compartment B
ICB
Pharmaceuticals
Operation
IPO date
IPO price
EUR 3.60
Issue type
Initial Public offering
Cat├ęgorie
IPO
Price range
EUR 3.60 - EUR 4.60

Company profile

Acacia Pharma Group specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2018, the group had a portfolio of 2 products, including APD403 in phase II of clinical development (treatment of chemically induced nausea and vomiting) and Baremsys in pre-launch phase (treatment of nausea and postoperative vomiting).

Source: Cofisem - Last Update: 17 Jan 2020
Key Executives
Chief Executive Officer Julian Gilbert
Company Secretary Christine Soden
Chief Financial Officer Christine Soden
VP, Investor Relations Christine Soden
Source: Cofisem - Last Update: 22 Mar 2019
Key figures
Millenium 2018 2017 2016 2015
Net sales
Income from ordinary activities
Operating income -17,611 -3,529 -16,917 -14,603
Cost (net) of financial indebtedness 8 22
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -18,177 -7,229 -15,810 -15,080
Net income (Group share) -18,177 -7,229 -15,810 -15,080
Fiscal year end 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 17 Jan 2020
Shareholder information
Gilde Healthcare Partners 32.00 %
Lundbeckfond Invest 23.60 %
Novo 14.40 %
F-Prime 9.30 %
AXA Investment Managers 5.10 %
Source: Cofisem - Last Update: 22 Mar 2019